{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:47:31Z","timestamp":1792097251895,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","award":["D55E11002680005"],"award-info":[{"award-number":["D55E11002680005"]}],"id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Microvascular complications (MC) have been claimed to increase the risk for cardiovascular disease in diabetic subjects. However, the effect of MC burden on the risk of major vascular outcomes and all-cause mortality in type 1 diabetes is still poorly explored. We evaluated the relationship between microvascular complications burden and incidence of major cardiovascular events and all-cause mortality in subjects with type 1 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited 774 participants with type 1 diabetes in a single-center observational study over a follow-up of 10.8\u2009\u00b1\u20092.5\u00a0years. Hazard ratios (HR) for cardiovascular outcomes and all-cause death associated with microvascular complications were determined by unadjusted and adjusted Cox regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 774 individuals, 54.9% had no-MC, 32.3% 1 MC, 9.7% 2 MC and 3.1% 3 MC. A total of 54 deaths (7.0%) occurred. Death rate increased from no-MC 2.1% (Ref) to 1 MC 7.2% (HR 3.54 [95% CI 1.59\u20137.87]), 2 MC 14.7% (HR 6.41 [95% CI 2.65\u201315.49]) and 3 MC 66.7% (HR 41.73 [95% CI 18.42\u201394.57], p\u2009&lt;\u20090.0001). After adjustments, HRs were: 1 MC 2.05 (95% CI 0.88\u20134.76), 2 MC 1.98 (95% CI 0.75\u20135.21), 3 MC 7.02 (95% CI 2.44\u201320.20, p\u2009=\u20090.002). Forty-nine subjects (6.7%) had at least one cardiovascular event, and cumulative incidence went from no-MC 2.2% (Ref) to 1 MC 5.0%; (HR 2.27 [95% CI 0.96\u20135.38]), 2 MC 26.8% (HR 12.88 [95% CI 5.82\u201328.50]) and 3 MC 40.9% (HR 29.34 [95% CI 11.59\u201374.25], p\u2009&lt;\u20090.0001). Upon adjustments, HRs were: 1 MC 1.59 (95% CI 0.65\u20133.88), 2 MC 4.33 (95% CI 1.75\u201310.74), 3 MC 9.31 (95% CI 3.18\u201327.25, p\u2009&lt;\u20090.0001). Thirty-five individuals (4.8%) had at least one coronary event, which cumulative incidence increased with MC burden (p\u2009&lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In type 1 diabetes, microvascular complications burden increases in an independent dose-dependent manner the risk of major cardiovascular outcomes and all-cause mortality. The presence and number of microvascular complications should be considered in stratifying overall cardiovascular risk in type 1 diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-019-0961-7","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T15:01:27Z","timestamp":1573916487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study"],"prefix":"10.1186","volume":"18","author":[{"given":"Monia","family":"Garofolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gualdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aragona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Miccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Francesconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-0270","authenticated-orcid":false,"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Penno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,16]]},"reference":[{"issue":"15","key":"961_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318.","journal-title":"N Engl J Med"},{"issue":"8","key":"961_CR2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/dc15-2399","volume":"39","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2016","unstructured":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT\/EDIC versus the general population. Diabetes Care. 2016;39(8):1378\u201383.","journal-title":"Diabetes Care"},{"issue":"12","key":"961_CR3","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2337\/dc10-1170","volume":"33","author":"AM Secrest","year":"2010","unstructured":"Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care. 2010;33(12):2573\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"961_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-005-0120-4","volume":"49","author":"SS Soedamah-Muthu","year":"2006","unstructured":"Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992\u20131999. Diabetologia. 2006;49(4):660\u20136.","journal-title":"Diabetologia"},{"issue":"11","key":"961_CR5","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00125-013-3025-7","volume":"56","author":"ME J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen ME, Almdal TP, Carstensen B. Time trends in mortality rates in type 1 diabetes from 2002 to 2011. Diabetologia. 2013;56(11):2401\u20134.","journal-title":"Diabetologia"},{"issue":"6","key":"961_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00125-016-3914-7","volume":"59","author":"D Petrie","year":"2016","unstructured":"Petrie D, Lung TW, Rawshani A, Palmer AJ, Svensson AM, Eliasson B, et al. Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia. 2016;59(6):1167\u201376.","journal-title":"Diabetologia"},{"issue":"6","key":"961_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00125-015-3857-4","volume":"59","author":"L Huo","year":"2016","unstructured":"Huo L, Harding JL, Peeters A, Shaw JE, Magliano DJ. Life expectancy of type 1 diabetic patients during 1997\u20132010: a national Australian registry-based cohort study. Diabetologia. 2016;59(6):1177\u201385.","journal-title":"Diabetologia"},{"issue":"16","key":"961_CR8","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.116.025961","volume":"135","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, et al. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135(16):1522\u201331.","journal-title":"Circulation"},{"issue":"21","key":"961_CR9","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"Lind M, Svensson AM, Kosiborod M, Gudbj\u00f6rnsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972\u201382.","journal-title":"N Engl J Med"},{"issue":"11","key":"961_CR10","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1007\/s00125-014-3358-x","volume":"57","author":"SS Soedamah-Muthu","year":"2014","unstructured":"Soedamah-Muthu SS, Vergouwe Y, Costacou T, Miller RG, Zgibor J, Chaturvedi N, et al. Predicting major outcomes in type 1 diabetes: a model development and validation study. Diabetologia. 2014;57(11):2304\u201314.","journal-title":"Diabetologia"},{"issue":"11","key":"961_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058\u201366.","journal-title":"Circulation"},{"issue":"7","key":"961_CR12","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"PH Groop","year":"2009","unstructured":"Groop PH, Thomas MC, Moran JL, Wad\u00e8n J, Thorn LM, M\u00e4kinen VP, et al. FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651\u20138.","journal-title":"Diabetes"},{"issue":"6","key":"961_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2337\/diacare.28.6.1383","volume":"28","author":"MV van Hecke","year":"2005","unstructured":"van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, et al. EURODIAB prospective complications study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care. 2005;28(6):1383\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"961_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2337\/dc17-2250","volume":"41","author":"D Gordin","year":"2018","unstructured":"Gordin D, Harjutsalo V, Tinsley L, Fickweiler W, Sun JK, Forsblom C, et al. Differential association of microvascular attributions with cardiovascular disease in patients with long duration of type 1 diabetes. Diabetes Care. 2018;41(4):815\u201322.","journal-title":"Diabetes Care"},{"issue":"4","key":"961_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00125-019-4812-6","volume":"62","author":"L Bjerg","year":"2019","unstructured":"Bjerg L, Hulman A, Carstensen B, Charles M, Witte DR, J\u00f8rgensen ME. Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study. Diabetologia. 2019;62(4):633\u201343.","journal-title":"Diabetologia"},{"issue":"1","key":"961_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-018-0726-8","volume":"17","author":"A Pease","year":"2018","unstructured":"Pease A, Earnest A, Ranasinha S, Nanayakkara N, Liew D, Wischer N, et al. Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). Cardiovasc Diabetol. 2018;17(1):77.","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"961_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1055\/s-0043-113452","volume":"126","author":"T Heller","year":"2018","unstructured":"Heller T, Kloos C, Lehmann T, Schiel R, Lorkowski S, Wolf G, et al. Mortality and its causes in a german cohort with diabetes mellitus type 1 after 20 years of follow-up: the JEVIN Trial. Exp Clin Endocrinol Diabetes. 2018;126(6):387\u201393.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"961_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00125-017-4251-1","volume":"60","author":"G Penno","year":"2017","unstructured":"Penno G, Russo E, Garofolo M, Daniele G, Lucchesi D, Giusti L, et al. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia. 2017;60(6):1102\u201313.","journal-title":"Diabetologia"},{"issue":"3","key":"961_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/BF00398055","volume":"37","author":"J Stephenson","year":"1994","unstructured":"Stephenson J, Fuller JH. on behalf of the EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994;37(3):278\u201385.","journal-title":"Diabetologia"},{"issue":"8","key":"961_CR20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1515\/CCLM.2007.246","volume":"45","author":"A Mosca","year":"2007","unstructured":"International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division, Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, et al. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077\u201380.","journal-title":"Clin Chem Lab Med"},{"key":"961_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"issue":"9","key":"961_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"2","key":"961_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","volume":"54","author":"AS Levey","year":"2009","unstructured":"Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009;54(2):205\u201326.","journal-title":"Am J Kidney Dis"},{"key":"961_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"R Kumar","year":"2013","unstructured":"Kumar R. Kidney Disease: improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1\u2013150.","journal-title":"Kidney Int"},{"issue":"4","key":"961_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF00410281","volume":"38","author":"SJ Aldington","year":"1995","unstructured":"Aldington SJ, Kohner EM, Meuer S, Klein R, Sj\u00f8lie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia. 1995;38(4):437\u201344.","journal-title":"Diabetologia"},{"issue":"9","key":"961_CR26","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677\u201382.","journal-title":"Ophthalmology"},{"issue":"7","key":"961_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1464-5491.2012.03644.x","volume":"29","author":"WH Herman","year":"2012","unstructured":"Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. DCCT\/EDIC Research Group. Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications. Diabet Med. 2012;29(7):937\u201344.","journal-title":"Diabet Med"},{"issue":"3","key":"961_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/1932296814527818","volume":"8","author":"L Maffei","year":"2014","unstructured":"Maffei L, Premrou V, Roldan P, Copetti M, Pellegrini F, Rossi MC, et al. Vibration perception threshold in the screening of sensorimotor distal symmetric polyneuropathy: the need of more accurate age-specific reference values. J Diabetes Sci Technol. 2014;8(3):621\u20132.","journal-title":"J Diabetes Sci Technol."},{"key":"961_CR29","volume-title":"The minnesota code manual of electrocardiographic findings","author":"RJ Prineas","year":"1982","unstructured":"Prineas RJ, Crow RS, Blackburn H. The minnesota code manual of electrocardiographic findings. Boston: JohnWright-PSG; 1982."},{"issue":"12","key":"961_CR30","doi-asserted-by":"publisher","first-page":"H1729","DOI":"10.1152\/ajpheart.00372.2014","volume":"307","author":"CJ Lockhart","year":"2014","unstructured":"Lockhart CJ, McCann AJ, Pinnock RA, Hamilton PK, Harbinson MT, McVeigh GE. Multimodal functional and anatomic imaging identifies preclinical microvascular abnormalities in type 1 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2014;307(12):H1729\u201336.","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"1","key":"961_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12933-018-0718-8","volume":"17","author":"C Blanc-Bisson","year":"2018","unstructured":"Blanc-Bisson C, Velayoudom-Cephise FL, Cougnard-Gregoire A, Helmer C, Rajaobelina K, Delcourt C, et al. Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study. Cardiovasc Diabetol. 2018;17(1):82.","journal-title":"Cardiovasc Diabetol."},{"issue":"9","key":"961_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dme.13651","volume":"35","author":"K Yozgatli","year":"2018","unstructured":"Yozgatli K, Lefrandt JD, Noordzij MJ, Oomen PHN, Brouwer T, Jager J, et al. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in type 2 diabetes mellitus. Diabet Med. 2018;35(9):1242\u20138.","journal-title":"Diabet Med"},{"issue":"1","key":"961_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-017-0570-2","volume":"16","author":"M Heier","year":"2017","unstructured":"Heier M, Borja MS, Brunborg C, Seljeflot I, Margeirsdottir HD, Hanssen KF, et al. Reduced HDL function in children and young adults with type 1 diabetes. Cardiovasc Diabetol. 2017;16(1):85.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"961_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-017-0539-1","volume":"16","author":"SA Peeters","year":"2017","unstructured":"Peeters SA, Engelen L, Buijs J, Jorsal A, Parving HH, Tarnow L, et al. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol. 2017;16(1):55.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"961_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-018-0706-z","volume":"17","author":"M Carbonell","year":"2018","unstructured":"Carbonell M, Castelblanco E, Valldeperas X, Betriu \u00c0, Traveset A, Granado-Casas M, et al. Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type\u00a01\u00a0diabetes. Cardiovasc Diabetol. 2018;17(1):66.","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"961_CR36","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.2337\/dc18-1236","volume":"41","author":"JA Lovshin","year":"2018","unstructured":"Lovshin JA, Bjornstad P, Lovblom LE, Bai JW, Lytvyn Y, Boulet G, et al. Atherosclerosis and microvascular complications: results from the canadian study of longevity in type 1 diabetes. Diabetes Care. 2018;41(12):2570\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"961_CR37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S2213-8587(16)30057-2","volume":"4","author":"JR Brownrigg","year":"2016","unstructured":"Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016;4(7):588\u201397.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"961_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2352-4642(18)30309-2","volume":"3","author":"KA Sauder","year":"2019","unstructured":"Sauder KA, Stafford JM, Mayer-Davis EJ, Jensen ET, Saydah S, Mottl A, et al. SEARCH for Diabetes in Youth Study Group. Co-occurrence of early diabetes-related complications in adolescents and young adults with type 1 diabetes: an observational cohort study. Lancet Child Adolesc Health. 2019;3(1):35\u201343.","journal-title":"Lancet Child Adolesc Health."},{"issue":"11","key":"961_CR39","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.2337\/dc15-0641","volume":"38","author":"LM Thorn","year":"2015","unstructured":"Thorn LM, Gordin D, Harjutsalo V, H\u00e4gg S, Masar R, Saraheimo M, et al. FinnDiane Study Group. The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2015;38(11):2128\u201333.","journal-title":"Diabetes Care"},{"issue":"6","key":"961_CR40","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jdiacomp.2018.03.012","volume":"32","author":"M Garofolo","year":"2018","unstructured":"Garofolo M, Russo E, Miccoli R, Lucchesi D, Giusti L, Sancho-Bornez V, et al. Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: association with major vascular outcomes risk and all-cause mortality. J Diabetes Compl. 2018;32(6):550\u20137.","journal-title":"J Diabetes Compl"},{"issue":"12","key":"961_CR41","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1111\/dom.13456","volume":"20","author":"V Harjutsalo","year":"2018","unstructured":"Harjutsalo V, Thomas MC, Forsblom C, Groop PH, FinnDiane Study Group. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 2018;20(12):2759\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"961_CR42","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2337\/dc18-1125","volume":"41","author":"ML Marcovecchio","year":"2018","unstructured":"Marcovecchio ML, Chiesa ST, Armitage J, Daneman D, Donaghue KC, Jones TW, et al. Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) Study Group. Renal and cardiovascular risk according to tertiles of urinary albumin-to-creatinine ratio: the adolescent type 1 diabetes cardio-renal intervention trial (AdDIT). Diabetes Care. 2018;41(9):1963\u20139.","journal-title":"Diabetes Care"},{"issue":"7","key":"961_CR43","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc08-0107","volume":"31","author":"SS Soedamah-Muthu","year":"2008","unstructured":"Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH. EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008;31(7):1360\u20136.","journal-title":"Diabetes Care"},{"issue":"7","key":"961_CR44","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.2337\/db11-1235","volume":"61","author":"UM Mogensen","year":"2012","unstructured":"Mogensen UM, Jensen T, K\u00f8ber L, Kelb\u00e6k H, Mathiesen AS, Dixen U, et al. Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients. Diabetes. 2012;61(7):1822\u201330.","journal-title":"Diabetes"},{"issue":"1","key":"961_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2337\/dc16-1397","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Braffett BH, Zinman B, Martin C, White NH, Herman WH, et al. DCCT\/EDIC Research Group. cardiovascular autonomic neuropathy and cardiovascular outcomes in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) study. Diabetes Care. 2017;40(1):94\u2013100.","journal-title":"Diabetes Care"},{"issue":"12","key":"961_CR46","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.2337\/dc18-0476","volume":"41","author":"D Pongrac Barlovic","year":"2018","unstructured":"Pongrac Barlovic D, Harjutsalo V, Gordin D, Kallio M, Forsblom C, King G, et al. FinnDiane Study Group. The association of severe diabetic retinopathy with cardiovascular outcomes in long-standing type 1 diabetes: a longitudinal follow-up. Diabetes Care. 2018;41(12):2487\u201394.","journal-title":"Diabetes Care"},{"issue":"12","key":"961_CR47","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s00125-018-4725-9","volume":"61","author":"M Feodoroff","year":"2018","unstructured":"Feodoroff M, Harjutsalo V, Forsblom C, Groop PH, FinnDiane Study Group. Dose-dependent effect of smoking on risk of coronary heart disease, heart failure and stroke in individuals with type 1 diabetes. Diabetologia. 2018;61(12):2580\u20139.","journal-title":"Diabetologia"},{"issue":"3","key":"961_CR48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/dom.13550","volume":"21","author":"I Pearce","year":"2019","unstructured":"Pearce I, Sim\u00f3 R, L\u00f6vestam-Adrian M, Wong DT, Evans M. Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. Diabetes Obes Metab. 2019;21(3):467\u201378.","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"961_CR49","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.03.009","volume":"25","author":"VY Guo","year":"2016","unstructured":"Guo VY, Cao B, Wu X, Lee JJW, Zee BC. Prospective association between diabetic retinopathy and cardiovascular disease-a systematic review and meta-analysis of cohort studies. J Stroke Cerebrovasc Dis. 2016;25(7):1688\u201395.","journal-title":"J Stroke Cerebrovasc Dis."},{"issue":"5","key":"961_CR50","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00125-018-4564-8","volume":"61","author":"FJ Jansson","year":"2018","unstructured":"Jansson FJ, Forsblom C, Harjutsalo V, Thorn LM, Wad\u00e9n J, Elonen N, et al. FinnDiane Study Group. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study. Diabetologia. 2018;61(5):1203\u201311.","journal-title":"Diabetologia"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0961-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0961-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0961-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T20:15:04Z","timestamp":1665000904000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0961-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0961-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,16]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local ethics committee approved the study protocol, and the study was carried out in accordance with Declaration of Helsinki. Each participant signed a written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG has received travel grants from AstraZeneca and Novo Nordisk. MA has received speaker\/advisory honoraria from Abbott Laboratories. FC has received travel grants from Novo Nordisk. GD reports past participation in advisory boards from AstraZeneca, Eli Lilly and Co and Novartis Pharmaceuticals. SDP reports past participation in advisory boards and\/or receiving research grants from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, Sanofi, Servier, and Takeda Pharmaceuticals. GP has received travel grants and speaker\/advisory honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck Sharp & Dohme, Mundipharma Pharmaceuticals,\u00a0Novo Nordisk, and Takeda Pharmaceuticals. All other authors (EG, RG, DL, MR, and PF) declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}